Literature DB >> 22014897

Omitting elective nodal irradiation during thoracic irradiation in limited-stage small cell lung cancer--evidence from a phase II trial.

Rovel Colaco1, Hamid Sheikh, Paul Lorigan, Fiona Blackhall, Paul Hulse, Raffaele Califano, Linda Ashcroft, Paul Taylor, Nicholas Thatcher, Corinne Faivre-Finn.   

Abstract

Omitting elective nodal irradiation (ENI) in limited-stage disease small cell lung cancer (LD-SCLC) is expected to result in smaller radiation fields. We report on data from a randomised phase II trial that omitted ENI in patients receiving concurrent chemo-radiotherapy for LD-SCLC. 38 patients with LD-SCLC were randomised to receive once-daily (66 Gy in 33 fractions) or twice-daily (45 Gy in 30 fractions) radiotherapy (RT). 3D-conformal RT was given concurrently with cisplatin and etoposide starting with the second cycle of a total of four cycles. The gross tumour volume was defined as primary tumour with involved lymph nodes (nodes ≥1 cm in short axis) identifiable with CT imaging. ENI was not used. Six recurrence patterns were identified: recurrence within planning target volume (PTV) only, recurrence within PTV+regional nodal recurrence and/or distant recurrence, isolated nodal recurrence outside PTV, nodal recurrence outside PTV+distant recurrence, distant metastases only and no recurrence. At median follow-up 16.9 months, 31/38 patients were evaluable and 14/31 patients had relapsed. There were no isolated nodal recurrences. Eight patients relapsed with intra-thoracic disease: 2 within PTV only, 4 within PTV and distantly and 2 with nodal recurrence outside PTV plus distant metastases. Rates of grade 3+ acute oesophagitis and pneumonitis in the 31 evaluable patients were 23 and 3% respectively. In our study of LD-SCLC, omitting ENI based on CT imaging was not associated with a high risk of isolated nodal recurrence, although further prospective studies are needed to confirm this. Routine ENI omission will be further evaluated prospectively in the ongoing phase III CONVERT trial (NCT00433563). Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22014897     DOI: 10.1016/j.lungcan.2011.09.015

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  Management of small-cell lung cancer with radiotherapy-a pan-Canadian survey of radiation oncologists.

Authors:  J Shahi; J R Wright; Z Gabos; A Swaminath
Journal:  Curr Oncol       Date:  2016-06-09       Impact factor: 3.677

2.  Stereotactic body radiotherapy with concurrent chemotherapy extends survival of patients with limited stage small cell lung cancer: a single-center prospective phase II study.

Authors:  Chongyi Li; Yanli Xiong; Zejun Zhou; Yu Peng; Huan Huang; Mingfang Xu; Houyi Kang; Bo Peng; Dong Wang; Xueqin Yang
Journal:  Med Oncol       Date:  2014-11-22       Impact factor: 3.064

3.  Stereotactic body radiation therapy for the treatment of a post-chemotherapy remnant lung mass in extensive-stage small-cell lung cancer: A case report.

Authors:  Seung-Gu Yeo; Min-Jeong Kim
Journal:  Exp Ther Med       Date:  2016-05-18       Impact factor: 2.447

Review 4.  Assessing the interactions between radiotherapy and antitumour immunity.

Authors:  Clemens Grassberger; Susannah G Ellsworth; Moses Q Wilks; Florence K Keane; Jay S Loeffler
Journal:  Nat Rev Clin Oncol       Date:  2019-06-26       Impact factor: 66.675

5.  Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy.

Authors:  Rebecca Bütof; Calogero Gumina; Chiara Valentini; Antje Sommerer; Steffen Appold; Daniel Zips; Steffen Löck; Michael Baumann; Esther G C Troost
Journal:  Clin Transl Radiat Oncol       Date:  2017-11-06

6.  Impact of radiation dose on concurrent chemoradiotherapy for limited-stage small-cell lung cancer.

Authors:  Junhee Park; Min Kyu Kang
Journal:  Radiat Oncol J       Date:  2018-03-30

7.  Feasibility of tomotherapy-based image-guided radiotherapy for small cell lung cancer.

Authors:  Nam P Nguyen; Wei Shen; Sarah Kratz; Jacqueline Vock; Paul Vos; Vinh-Hung Vincent; Gabor Altdorfer; Lars Ewell; Siyoung Jang; Ulf Karlsson; Juan Godinez; Melissa Mills; Thomas Sroka; Suresh Dutta; Alexander Chi
Journal:  Front Oncol       Date:  2013-11-26       Impact factor: 6.244

Review 8.  Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review.

Authors:  Lucheng Zhu; Shirong Zhang; Xiao Xu; Bing Wang; Kan Wu; Qinghua Deng; Bing Xia; Shenglin Ma
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

9.  Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.

Authors:  Corinne Faivre-Finn; Sally Falk; Linda Ashcroft; Michelle Bewley; Paul Lorigan; Elena Wilson; Nicki Groom; Michael Snee; Pierre Fournel; Felipe Cardenal; Andrea Bezjak; Fiona Blackhall
Journal:  BMJ Open       Date:  2016-01-20       Impact factor: 2.692

10.  A Meta-Analysis of the Efficacy and Toxicity of Twice-Daily vs. Once-Daily Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer Based on Randomized Controlled Trials.

Authors:  Qian Wu; Yiting Xiong; Shujuan Zhang; Xinling Chen; Fengming Yi; Yiping Wei; Wenxiong Zhang
Journal:  Front Oncol       Date:  2020-01-08       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.